Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAS-106521
- Development stage
- Unknown
- Lead developer
- Almirall
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
LAS-106521 is a topical agent developed for the treatment of actinic keratosis, a precancerous skin condition characterized by rough, scaly patches on sun-exposed areas. The drug was investigated in clinical trials as a gel formulation applied twice daily. Almirall was the developer of LAS-106521[1][2][3]. Its precise mechanism of action has not been publicly disclosed.
Beyond the preview
Go deeper on LAS-106521.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAS-106521.